Pierre Mangin

Title: Pierre Mangin: Innovator in Cancer Treatment

Introduction

Pierre Mangin is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on methods and pharmaceutical compositions aimed at the prophylactic treatment of metastases.

Latest Patents

Pierre Mangin holds a patent for "Methods and pharmaceutical compositions for the prophylactic treatment of metastases." This invention relates to methods and pharmaceutical compositions designed to prevent metastases in cancer patients. The research demonstrated that lung metastasis in GPVI deficient mice is reduced compared to controls. It was shown that GPVI plays a crucial role in platelet interaction with tumor cells, mediated by EMMPRIN. By utilizing an anti-EMMPRIN antibody, the adhesion of platelets to tumor cells was found to be decreased. The patent outlines a method for treating metastases in cancer patients by administering a therapeutically effective amount of an agent that inhibits the interaction between GPVI and EMMPRIN.

Career Highlights

Throughout his career, Pierre Mangin has worked with esteemed institutions such as the National Institute of Health and Medical Research and the Université de Strasbourg. His research has contributed to a deeper understanding of cancer metastasis and potential treatment options.

Collaborations

Pierre Mangin has collaborated with notable professionals in his field, including Christian Gachet. Their joint efforts have advanced the research on cancer treatment and the mechanisms involved in metastasis.

Conclusion

Pierre Mangin's innovative work in the field of cancer treatment highlights the importance of research and development in combating diseases. His patent and collaborations reflect a commitment to improving patient outcomes through scientific advancements.